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S U M M A R Y
Background: HIV-infected women have a high prevalence of human papillomavirus (HPV) infection and
are more likely to be infected with HPV genotypes that are considered high-risk and have the potential
for progressing to cervical cancer. The currently available HPV vaccines protect against speciﬁc HPV
genotypes that may not be the most important causes of dysplasia and potentially of cervical cancer in
HIV-1-infected women. African women have been underrepresented in the studies of global prevalence
of HPV genotypes.
Methods: We compared the HPV genotype distribution in HIV-1-infected women from Seattle,
Washington, USA and Nairobi, Kenya. The reverse line blot assay and DNA sequencing on cervicovaginal
lavage (CVL) specimens were carried out.
Results: Themost commonly detectedHPV types among thewomen from Seattlewere HPV 56, 66,MM8,
and 81; in contrast HPV 53, 33, and 58 were the most common HPV genotypes detected in the CVL
specimens from the women in the Nairobi cohort. The HPV types associated with low-grade squamous
intraepithelial lesions (LSIL) were HPV 53 and HPV 56. HPV types 58, 52, and 16 were associated with
high-grade squamous intraepithelial lesions (HSIL).
Conclusions: A better understanding of HPV genotype distribution in the most affected regions of the
world is essential to planning effective vaccine strategies if we are unable to demonstrate cross-
protection between HPV genotypes included in the present vaccines and those prevalent in the different
populations.
 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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With the recent introduction of two human papillomavirus
(HPV) vaccines, the acquisition of knowledge regarding the
distribution of HPV genotypes among geographic and biological
subgroups has become increasingly important. While the efﬁcacy
of both the bivalent (Cervarix; GlaxoSmithKline) and quadrivalent
(Gardasil; Merck and Co., Inc.) vaccines has been well documen-§ Presented in part at the International AIDS Conference in Mexico City, Mexico,
August 2008 (abstract THAC0306).
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doi:10.1016/j.ijid.2010.03.016ted,1–5 the effectiveness of these vaccines in curbing the incidence
of cervical cancer will be dependent, in large part, upon the
prevalence of oncogenic vaccine genotypes (HPV 16 and 18) in a
given population.
Global prevalence studies suggest that the two oncogenic HPV
genotypes included in the available vaccines, HPV 16 and 18 (the
quadrivalent vaccine also protects against HPV 6 and 11, which
cause genital warts but are low risk with regards to cervical
cancer), account for approximately 70% of cervical cancer
worldwide.6–8 Extrapolating from this data, it is easy to conclude
that the widespread use of the highly efﬁcacious current vaccines
has the potential to decrease the incidence of cervical cancer by a
similar percentage. Unfortunately, as data describing the distribu-
tion of HPV genotypes among subgroups of women from differentses. Published by Elsevier Ltd. All rights reserved.
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1 infection, accumulates, the relative prevalence of oncogenic
vaccine genotypes compared with non-vaccine oncogenic geno-
types among these groups is seen to lessen and the potential
impact of the current vaccines to diminish correspondingly.
We compared the HPV genotype distribution between HIV-1-
infectedwomen from Seattle,Washington, USA and Nairobi, Kenya
in order to assess the prevalence of HPV genotypes in two
geographically distinct populations when superimposed upon the
impact of HIV-1 co-infection.
Materials and methods
Study subjects
HIV-1-infected women were recruited from the Northwest
Family Center, Madison Clinic and from the University of
Washington Adult AIDS Clinical Trials Units (ACTU), which are
located at Harborview Medical Center in downtown Seattle and
together provide medical care for about 225 women annually.
Nairobi women were enrolled from the Center for Respiratory
Disease Research at the Kenya Medical Research Institute in
Nairobi, Kenya, where 250 HIV-1-infected women are followed.
Pre-menopausal women between the ages of 13 and 50 years with
a documented HIV-1 infection who were able to provide informed
consent and did not have a history of hysterectomy or high-grade
squamous intraepithelial lesions (HSIL) on cervical cytology were
invited to participate. A total of 38women from the Seattle site and
50women fromNairobi agreed to participate in the study.Women
fromNairobiwere required to have a CD4+ cell count of350 cells/
mm3, but there were no restrictions on CD4+ cell count for women
in the Seattle cohort.
After completing informed consent procedures, study subjects
underwent a standardized history and physical examination. A
questionnaire, administered to all study subjects, included
questions regarding lifetime number of sexual partners, condom
use, and oral contraceptive use.
Collection of specimens
Subjects collected a urine sample for ampliﬁcation testing for
chlamydia andgonorrheadetection. Specimens of cervical cellswere
obtained using the Cervex-Brush (Rovers Medical Devices) and
spatula for theexocervix.Cervicovaginal lavage (CVL)wasperformed
using 10ml of phosphate-buffered saline (PBS) placed in a syringe
attached to a plastic pipette. The cervix was bathed three times and
liquidwas collected fromtheposterior fornixusing the samesyringe.
CVL specimens were frozen in aliquots at70 8C, shipped in dry ice,
and stored at 70 8C until HPV DNA testing was performed.
Blood was collected for CD4+ cell counts, and was processed at
each site. For HIV RNA determinations, blood was collected into
vacutainer ethylenediaminetetraacetic acid (EDTA) tubes and
separated within 6 h of collection. Plasma samples from study
participants at the Nairobi site were frozen at 80 8C and shipped
on dry ice to the University ofWashington in Seattle for processing.
Specimen processing
Urine was tested, at each site, by similar ampliﬁcation methods
for gonorrhea and chlamydia.
Lymphocyte markers (CD4+ counts) were determined by
standard ﬂow cytometric methods at either the Kenya Medical
Research Institute in Nairobi or the University of Washington in
Seattle.
For both cohorts, plasma was processed at the University of
Washington in Seattle and HIV RNA measured using a real-timereverse transcriptase PCR (real-time RT-PCR)with a detection limit
of 30–1 000 000 copies/ml (bioMe´rieux, Inc., Durham, NC, USA).
For cervical cytology, slides were read by local staff pathologists
at the respective sites and results were reported according to the
2001 Bethesda System for cervical cytology reporting. Pap smears
were considered abnormal if they contained atypical squamous
cells of undetermined signiﬁcance (ASCUS), low-grade squamous
intraepithelial lesions (LSIL), or high-grade squamous intraepithe-
lial lesions (HSIL).
Testing of CVL samples for HPV genotypes
Total DNA was extracted from each lavage specimen using a
commercial kit (Epicentre Technologies, Madison, WI, USA).
PCR ampliﬁcation was performed by adding puriﬁed specimen
total DNA to previously prepared buffer containing Amplitaq Gold
(Applied Biosystems, Foster City, CA, USA), MY09/MY11 primers,
and human b-globin primers.9 PCR reaction products were
analyzed by agarose gel electrophoresis, and ampliﬁed products
were detected by stainingwith ethidiumbromide. Specimenswere
scored positive if they contained ampliﬁcation products of
expected sizes for bothMY09/11 andb-globin amplicons. Samples
meeting these criteria were then subjected to genotype analysis.
The reverse line blot assay was performed using a modiﬁcation
of previously described methods.9,10 Each ampliﬁed biotinylated
product was hybridized to a set of 27 immobilized oligonucleotide
probes, each corresponding to an individual HPV genotype.
Specimens positive for HPV DNA by PCR but negative by reverse
line blot were sequenced.
Statistical analyses
Differences between cities in baseline demographic variables
were assessed using a t-test, a Wilcoxon rank sum test, or Fisher’s
exact test, as appropriate to the data. To discern the relationship
between HPV genotypes, geographical location, and cervical
cytology, proportions of patients with abnormal Pap smears with
their 95% conﬁdence intervals (95% CI), employing the asymptotic
standard error, are reported. These proportions were assessed for
ﬁrst visit data for those patients with CD4+ counts >350 cells/
mm3. In an attempt to summarize the associations, exploratory
logistic regressions evaluated the regression of the cervical
cytology variable dichotomized to represent any type of abnormal
Pap smear vs. results that were within normal limits on
categorized HPV type, trichotomized as no HPV type, only low-
risk HPV type, or high-risk HPV type. Cervical cytology was also
regressed on number of HPV types, which were categorized as
none, single HPV type, or more than one HPV type. The association
of cervical cytology and cohort was also evaluated.
Results
Study population
Among the 38women enrolled in Seattle, 20 (53%) were African
American, 12 (32%) were Caucasian, two (5%) Asian or Paciﬁc
Islander, two (5%) Hispanic, one (3%) Native American, and one of
unspeciﬁed race/ethnicity (3%). The mean age at enrollment for
this group was 38.3  6.6 years, themedian CD4+ cell count was 346
cells/mm3, and the median HIV RNA was 1036 copies/ml of plasma.
The 50 women enrolled in Nairobi had a mean age at enrollment of
32.7  5.0 years, had a median CD4+ cell count of 538 cells/mm3, and
a median HIV RNA of 13 942 copies/ml. Among women in the Nairobi
cohort, 24 (48%) identiﬁed themselves as belonging to the Kikuyu
ethnic group, eight (16%) to the Luo, six (12%) to the Luhya, and three
(6%) to the Kamba; nine (18%) were listed as ‘unknown ethnic group’
Table 1
Baseline characteristics of the study population, stratiﬁed by site
Seattle (n=38) Nairobi (n=50)
Age (years) mean SD 38.36.6 32.75.0
Parity 2.52.1 2.62.3
Race/ethnicity, n (%)
Caucasian 12 (32) -
African American 20 (53) -
Asian/Paciﬁc Islander 2 (5) -
Hispanic 2 (5) -
Native American 1 (3) -
Other 1 (3) -
Kikuyu 24 (48)
Luo 8 (16)
Luhya 6 (12)
Kamba 3 (6)
Other/unknown 9 (18)
HIV risk factor, n (%)a
IVDU 9 (24)
Heterosexual 25 (66)
Blood transfusion 2 (5)
Other/unknown 2 (5)
Lifetime sexual partners
Median (IQR) 11 (5–20) 3 (2–5)b
Oral contraceptive use, n (%)
Ever 29 (76) 30 (60)
Current 2 (5) 2 (4)
On ARVT, n (%) 20 (53) 0 (0)c
CD4+ cell count (cells/mm3),
median (range)
346 (30–1168) 538d (353–1316)
HIV RNA (copies/ml),
median (range)
1036
(<30–277 000)
13 942
(<30–588 000)
SD, standard deviation; IVDU, intravenous drug use; IQR, interquartile range; ARVT,
antiretroviral therapy.
a Nairobi women had acquired HIV exclusively by heterosexual transmission.
b p=0.04, Wilcoxon rank-sum test.
c p<0.0001, Fisher’s exact test.
d p=0.008, Wilcoxon rank-sum test.
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HIV exclusively via heterosexual sex, in contrast to the Seattle group
in which 25 (66%) women reported heterosexual contact as their HIV
risk factor, ninewomen (24%) reported injection drug use as their risk
factor, two women (5%) reported receipt of blood products as their
only HIV risk factor, and two women (5%) reported no HIV risk factor.
The use of oral contraceptives at any given time was reported by 29
women (76%) in the Seattle group and 30 women (60%) in the Nairobi
group. Only two women (5%) in the Seattle group and two (4%) in the
Nairobi group reported taking oral contraceptives at the time of study.
The median number of lifetime sexual partners was 11 (5–20) for the
Seattle group and 3 (2–5) for the Nairobi group. All women in the
Nairobi group were untreated, while 20 women (53%) in the Seattle
group were receiving antiretroviral therapy. The number of sexual
partners (p = 0.04), CD4+ cell count (p = 0.008), and antiretroviral
treatment (p < 0.0001) were signiﬁcantly different between the
groups at baseline (Table 1).
HPV genotypes
Eighty-four CVL samples collected from 35 of the 38 women
enrolled in Seattle and 49 of the 50 women enrolled in Nairobi
were tested for HPV genotypes. Of the 35 specimens available from
the Seattle cohort, 20 were b-globin-positive and nine were HPV
DNA-positive. Of the 49 samples available from women in the
Nairobi cohort 37 were b-globin-positive and 11 were HPV DNA-
positive.
Nine out of 35 (26%) CVL samples from women in the Seattle
cohort were positive for HPV DNA; a single HPV genotype was
detected in 3/9 (33%) positive CVL samples, dual HPV genotypes
were detected in 2/9 (22%) samples, and one sample had three HPV
genotypes detected. Three out nine (33%) samples had non-
typeable HPV DNA by reverse line blot and were sequenced and
reported as having a single HPV type each. Eleven out of 49 CVL
samples (22%) were positive for HPV DNA among women from the
Nairobi cohort; a single HPV genotypewas identiﬁed in 9/11 (82%),
dual HPV genotypes detected in one sample, and one had triple
HPV genotypes detected (Table 2).
The most common HPV genotypes detected in the specimens
from the Seattle cohort were HPV 56, 66, MM8, and 81, whichwere
detected in two samples each, followed by HPV 6,MM7, 33, 70, and
16 in one sample each. Themost commonHPV genotypes detected
in the CVL specimens from the Nairobi cohort were HPV 53, which
was detected in 3/11 (27%) samples containing HPV DNA, followed
by HPV 33 in two samples (18%) and HPV 58 in two samples (18%).
HPV 16, 18, 62, and MM8 were found in one sample each (9%)
(Table 2).
Pap smear results and HPV genotypes
Thirty-seven Pap smears were available from the 38 women
enrolled in Seattle and 46 Pap smears were available from the 50
women enrolled in Nairobi. Three Pap smears were deemed
inadequate for interpretation in the Nairobi group and oneTable 2
Results of HPV genotypes at initial visit, by site
Cohort Number of CVL samples HPV infections
Seattle (n=37) 35 Triple: 1
Dual: 2
Single: 6
Nairobi (n=50) 49 Triple: 1
Dual: 1
Single: 9
HPV, human papillomavirus; CVL, cervicovaginal lavage.
Numbers in bold type denote high-risk HPV types.specimen was missing in each cohort. We found a similar
proportion of subjects with cervical smear abnormalities across
sites, with 12% of the women in the Seattle group and 11% of the
women in the Nairobi group.
HPV types associated with LSIL were HPV 53 and HPV 56, while
HPV 58, 52, and 16 were associated with HSIL. The summary
results for HPV types are reported in Table 3. An increase in the
proportion of abnormal cervical smears is seen as the number of
HPVs increases, from no HPV types to one HPV type to more than
one HPV type. Similarly there is an increase in the proportion of
patients with abnormal Pap smear results that follows the
progression from no HPV infection to infection with low-risk
HPV to infection with high-risk HPV.
Women with more than one HPV type detected in CVL were
22.5 times more likely to have an abnormal Pap smear than those
with no HPV detected. Results of the univariate logistic regression
are reported in Table 4 and point to the increased odds for an
abnormal Pap smear given more than one HPV type, as well as inHPV types at initial visit (number of occurrences)
56 (2), 66 (2), MM8 (2), 81 (2), 70 (1), 6 (1), 16 (1), 33 (1), MM7 (1)
53 (3), 33 (2), 58 (2), 16 (1), 18 (1), 62 (1), MM8 (1)
Table 3
Proportion of women with abnormal cytology at initial visit by HPV number and
type and by city (subjects with CD4+ cell counts 350 cells/mm3 only)
Proportion of
abnormal Pap smears
95% conﬁdence
interval
Number of HPVs
No HPV type 0.08 0.01–0.16
Single HPV type 0.27 0.01–0.54
>Single HPV type 0.67 0.13–1.00
HPV type
No HPV type 0.08 0.01–0.16
Only low-risk HPV 0.33 0.00–0.87
High-risk HPV 0.40 0.10–0.70
Cohort
Seattle 0.11 0.00–0.27
Nairobi 0.15 0.05–0.26
HPV, human papillomavirus.
Table 4
Association of Pap smear results and HPV genotypes at initial visit for subjects with
CD4+ cell counts 350/mm3
ORa 95% CI p-Value
Number of HPVs
Single HPV type vs. no HPV type 4.22 0.79–22.53 0.09
>Single HPV type vs. no HPV type 22.50 1.66–305.73 0.02
HPV type
Only low-risk HPV vs. no HPV 5.63 0.42–76.43 0.19
High-risk HPV vs. no HPV 7.50 1.47–38.15 0.02
OR, odds ratio; CI, conﬁdence interval.
a OR reﬂects the odds of an abnormal Pap smear.
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(that is, low- or high-risk HPV) vs. no risk, reveals an odds ratio
(OR) of 7.03 (95% CI 1.55–32.00, p = 0.01). No association between
Pap smear results and cohort (Seattle vs. Nairobi) was found (OR
0.74, 95% CI 0.14–4.00, p = 0.73).
Discussion
In this study of two geographically distinct cohorts of HIV-1-
infected women, we detected multiple HPV genotypes in three out
of nine (33%) CVL specimens positive for HPV DNA collected from
women enrolled in Seattle, while only two out 11 (18%) CVL
specimens positive for HPV DNA from women from Nairobi had
multiple HPV detected. The most common HPV genotypes
detected among the Seattle cohort were 56 (22%), 66 (22%),
MM8 (22%), 81 (22%); HPV 70, 6, 16, 33, and MM7 were found in
11%. Themost commonHPV types detected in CVL specimens from
the Nairobi cohort were HPV 53 (27%), followed by HPV 33 (18%)
and HPV 58 (18%), with HPV 16, 18, 62 and MM8 detected in only
9%. Patients fromboth cohorts of this study had prevalence of high-
risk HPV types other than 16 and 18.
Abnormalities were noted in 8/37 Pap smears (22%) obtained
from the Seattle cohort and in 12/46 Pap smears (26%) from the
Nairobi cohort. There were differences in the abnormalities on
cervical cytology between cohorts. For the Seattle group, ASCUS
was reported in 50% of the abnormal Pap smears at initial visit, LSIL
in 37.5%, and HSIL in 12.5%, while in the Nairobi cohort 17% of the
abnormal Pap smears were reported as ASCUS, 25% as HSIL, and
17% as LSIL. Of the abnormal Pap smears, 42% were classiﬁed as
‘other’ (either reactive or regenerative changes). HPV types
associated with LSIL were HPV 53 and 56; HPV types 58, 52,
and 16 were associated with HSIL. When comparing abnormalities
in Pap smears using the data from only those women in the Seattlecohort whose CD4+ cell count was over 350 cells/mm3 and thus
similar to the women from Nairobi for whom a CD4+ cell count
over 350 cells/mm3 was part of the entry criteria, we found a
similar proportion of subjects with cervical smear abnormalities
across sites, with 12% of thewomen in the Seattle group and 11% of
the women in the Nairobi group.
Inspection of the proportions in Table 3 and the odds ratios in
Table 4 demonstrates that women with more than one HPV type
detected in CVL were 22.5 times more likely to have an abnormal
Pap smear than those with no HPV detected. Women were 7.50
times more likely to have an abnormal Pap smear when they had
high-risk HPV present vs. none. These results should be interpreted
with caution, given the very large 95% CI, which reﬂect a small
sample size. This qualiﬁcation holds true for the reported
proportions as well, where the 95% CI are also broad.
In light of the aforementioned caveat, we note that the results of
this current study are in concordance to our previous study of HPV
genotype distribution amongHIV-infectedwomen fromRochester,
NY, in which HPV 16 and HPV 18 were found to be only the 3rd and
9th most prevalent high-risk HPV genotypes, respectively.11 Our
results are also in agreement with a meta-analysis that included
data from over 5500 HIV-infected women, in which several non-
vaccine oncogenic HPV genotypeswere found to bemore prevalent
than HPV 16 among HIV-infected women with HSIL, including
genotypes 51, 52, and 58.12 Moreover, a distribution of high-risk
HPV that demonstrates a decreased relative prevalence of vaccine
types has been conﬁrmed in other African studies.13–20
The cause for the predominance of multiple HPV infections in
the Seattle cohort is not completely clear butmay be due in part to
the number of lifetime sexual partners, as participants from
Nairobi had signiﬁcantly fewer sexual partners (median lifetime
sexual partners 3, interquartile range (IQR) 2–5) than the
participants from Seattle (median life time sexual partners 11,
IQR 5–20). The difference in median CD4+ cell count was also
signiﬁcantly different. Preserved cellular immunity as measured
by CD4+ cell count may also have inﬂuenced the prevalence of
multiple HPV infection, with women from Nairobi having higher
CD4+ cell counts and lower prevalence of HPV infections with
multiple HPV types. The most common HPV genotypes detected
were also different in the two groups of women. Nevertheless,
both cohorts in this study had a higher prevalence of high-risk
HPV types other than HPV 16 and 18. Interestingly, the
relationship between immunosuppression (low vs. high CD4+
cell counts) andHPV16hasbeen reported as less pronounced than
for other HPV types.21 This was not evident in our study; however
our numbers are small and do not allow ﬁrm conclusions in this
regard.
The vast majority of global prevalence data for HPV genotypes
are based on studies of women from Europe and North America. It
is in the developing world, however, where most deaths from
cervical cancer occur.22,23 Africa in particular has been underrep-
resented in available data. Still, although African women only
accounted for 6% of cases in a meta-analysis of worldwide
distribution of HPV genotypes among womenwith cervical cancer,
these women were still found to have the lowest proportion of
cervical cancer cases attributable to HPV 16/18.7
AmoredetailedunderstandingofHPVgenotype distribution in
resource-poor regions of the globe is essential to planning
effective vaccine strategies, in particular if we are unable to
demonstrate cross-protection between HPV genotypes included
in the present vaccines and those prevalent in the different
populations.
Studying HPV in African women provides an opportunity to
assess the additive impact of HIV and regional differences in HPV
genotype distributions, and will assist with the development of
vaccine strategies that are appropriate for this population.
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